Canada's blood-supply watchdog is under scrutiny after a Health Canada inspection report raised serious concerns about private plasma donation clinics operating in Manitoba. The clinics, run by the company Grifols, which pays people for their blood products, came under the microscope following the deaths of two donors, an outcome that has revived difficult memories of past failures in the country's blood system.
At the heart of the concerns is who was allowed to donate. According to redacted documents from an inspection dated March 30, the company made changes so that unsuitable donors became eligible to give blood products, a shift that inspectors warned could compromise the safety of the supply. Critics say the risks to the blood system revealed by the reports are extraordinary.
Some of the findings are especially alarming. Inspectors reported that the company accepted donors with risks linked to variant CJD, or mad cow disease, a condition that is fatal. The reports also describe red flags that were ignored, including a donor taking too many medications, along with concerns that the operation ran over capacity and lacked personnel with the appropriate education, training or experience.
The two deaths that drew attention to the clinics remain unexplained in this context. One donor died after giving blood products at a Winnipeg clinic last year, and another died this year. Both the company and Health Canada, however, say the deaths have not been directly linked to the act of donating plasma, leaving the cause an open question even as the safety findings mount.
For its part, the company has pushed back on the most serious implications. Grifols says that no products were taken from donors with CJD risks and that at no time were donors or patients placed at risk. The statement seeks to reassure the public that, whatever the inspection found, the blood products themselves did not endanger anyone.
The regulator's response has drawn criticism. Health Canada restricted the company's licensing, including limiting appointments and mandating fully trained staff, but stopped short of shutting the operation down, allowing the clinics to stay open. Blood-safety advocates argue that is not enough, calling for the company to be closed to ensure Canada does not face another tainted-blood tragedy.
That fear is rooted in history. In the 1980s, contaminated blood infected about 2,000 Canadians with HIV and roughly 30,000 with hepatitis C, one of the darkest chapters in the country's health system. For advocates, the latest revelations are a warning that the hard lessons of that era must not be forgotten as private companies profit from Canadian blood.